Second Phase III study ESTABLISHes Trius antibiotic efficacy
This article was originally published in Scrip
Executive Summary
Now that a second set of Phase III data show that Trius Therapeutics' lower-dose antibiotic tedizolid is non-inferior to Pfizer's Zyvox (linezolid), the San Diego-based company is preparing to file applications for US and EU marketing approval within the next year.